Article
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
The New England journal of medicine - 3 Sept 2020
Wolf Jürgen, Seto Takashi, Han Ji-Youn, Reguart Noemi, Garon Edward B, Groen Harry J M, Tan Daniel S W, Hida Toyoaki, de Jonge Maja, Orlov Sergey V, Smit Egbert F, Souquet Pierre-Jean, Vansteenkiste Johan, Hochmair Maximilian, Felip Enriqueta, Nishio Makoto, Thomas Michael, Ohashi Kadoaki, Toyozawa Ryo, Overbeck Tobias R, de Marinis Filippo, Kim Tae-Min, Laack Eckart, Robeva Anna, Le Mouhaer Sylvie, Waldron-Lynch Maeve, Sankaran Banu, Balbin O Alejandro, Cui Xiaoming, Giovannini Monica, Akimov Mikhail, Heist Rebecca S
Abstract excerpt
BACKGROUND: Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation. METHODS: We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.